돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 98713생성일: 2026년 10월 24일

4-브로모-1-인다논

4-브로모-1-인다논 · 4-BROMO-2,3-DIHYDRO-1H-INDEN-1-ONE · SKL642 · OZAN-001 · 4-bromoindanone · 4-bromo-1-indanon · 4-BROMO-1-INDANONE · 4-Bromo-1-Indenone

https://huagongshe.com/ko/chemical/98713

4-브로모-1-인다논 분자 구조식

식별자 및 물리적 특성

CAS No.15115-60-3
분자식C9H7BrO
평균 분자량211.05 g/mol
단동위원소 질량209.96802694 g/mol
SMILESO=C1CCc2c(Br)cccc21
InChIKeyUVVYFYLSZIMKMC-UHFFFAOYSA-N
PubChem CID98713
ChEMBLCHEMBL1671941
EC No.628-019-5
DTXSIDDTXSID30164720
현지명4-브로모-1-인다논

화학 및 물리적 성질

XLogP2.4
극성 표면적17.1
수소 결합 공여자 수0
수소 결합 수용자 수1
회전 가능 결합 수0
무거운 원자 수11
형식 전하0
복잡도178
녹는점95-99 °C(lit.)
끓는 점125°C/1.5mmHg(lit.)
밀도1.608±0.06 g/cm3(Predicted)
저장 조건Sealed in dry,Room Temperature
물리적 상태결정성 분말
색상오렌지 브라운
InChIInChI=1S/C9H7BrO/c10-8-3-1-2-7-6(8)4-5-9(7)11/h1-3H,4-5H2
InChIKeyUVVYFYLSZIMKMC-UHFFFAOYSA-N
SMILESC1(=O)C2=C(C(Br)=CC=C2)CC1

화학적 성질

Orange-brown crystalline powder

안전 및 규제

GHS 분류WarningH302 (90.9%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 44 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard Classes and CategoriesAcute Tox. 4 (90.9%)
수질 위해 등급(WGK)2
RTECS 번호NK7536100
관세 코드29147000
위험 문구(R)22
위험 표시Xn
안전 문구(S)22-60-36
위험 등급Acute Tox. 4 Oral
저장 분류11 - Combustible Solids

용도

일반 설명

4-Bromo-1-indanone is an organic synthetic or pharmaceutical intermediate compound that can be used to prepare the prescription drug Ozanimod. Ozanimod can be used to treat relapsing multiple sclerosis (MS), including clinical solitary syndrome, relapsing-remitting disease and active secondary progressive disease. This drug cannot cure multiple sclerosis, but it can slow down some disabling effects and reduce the frequency of disease recurrence. It can also be used to treat moderate to severe ulcerative colitis.